Showing results (31-40 of 216) with videos related to
Sort By:
Pageof 22
Cancer Immunology, Immunotherapy : CII|August 14, 2021
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expressionHiroshi Takumida, Hidehito Horinouchi, Ken Masuda, et al.JTO Clinical and Research Reports|February 5, 2025
EGFR-Mutated Lung Adenocarcinoma With Li-Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case ReportHiroyuki Fujii, Yusuke Okuma, Makoto Hirata, et al.Lung Cancer (Amsterdam, Netherlands)|September 23, 2025
Unveiling the molecular and clinical risk landscape of second primary lung cancer in resected non-small cell lung cancerChihiro Takemura, Tatsuya Yoshida, Yukihiro Yoshida, et al.Clinical Lung Cancer|November 13, 2020
Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLCYuki Takeyasu, Tatsuya Yoshida, Ryota Shibaki, et al.Respiratory Investigation|July 4, 2024
The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomasTomohiro Tanaka, Yasushi Goto, Ken Masuda, et al.JTO Clinical and Research Reports|May 2, 2022
Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With AlectinibYuki Takeyasu, Tatsuya Yoshida, Ken Masuda, et al.Thoracic Cancer|March 27, 2019
Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancerNobumasa Tamura, Hidehito Horinouchi, Katsutoshi Sekine, et al.Journal of Cancer Research and Clinical Oncology|February 7, 2022
Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real worldSawako Kaku, Hidehito Horinouchi, Hirokazu Watanabe, et al.Thoracic Cancer|October 27, 2020
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibodyShuji Murakami, Ryota Shibaki, Yuji Matsumoto, et al.Lung Cancer (Amsterdam, Netherlands)|April 21, 2015
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancerMakoto Nishio, Atsushi Horiike, Haruyasu Murakami, et al.Pageof 22